TipRanks on MSN4h
Pfizer halts work on hemophilia gene therapy, Nikkei reportsPfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after ...
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback